The levels of the mononitrosyl iron complex with diethyldithiocarbamate that form in the liver of mice in vivo and in vitro after intraperitoneal injection of binuclear dinitrosyl iron complexes with N-acetyl-L-cysteine or glutathione, S-nitrosoglutathione, sodium nitrite, or the vasodilating drug isosorbide dinitrate (Isoket®) have been assessed by electron paramagnetic resonance (EPR). The levels of the complex in mice that received binuclear dinitrosyl iron complexes with thiol-containing ligands or S-nitrosoglutathione do not change after the treatment of liver preparations with the strong reducing agent dithionite, in contrast to those formed after nitrite or isosorbide dinitrate administration, whose levels sharply increase after the same treatment. It is inferred that in the latter case an EPR-active mononitrosyl iron complex with diethyldithiocarbamate is produced with the absence or presence of dithionite in the reaction of NO formed from nitrite with Fe²⁺-diethyldithiocarbamate and Fe³⁺-diethyldithiocarbamate complexes, respectively. In the former case, the mononitrosyl iron complex with diethyldithiocarbamate is produced by transition of iron-mononitrosyl fragments from already present iron-dinitrosyl groups of binuclear dinitrosyl complexes, whose content is three to four times higher than the content of the mononuclear form of these complexes in the tissue. The results we obtained indicate that when dinitrosyl iron complexes with thiol-containing ligands, either introduced into the body or produced with the participation of endogenous NO, appear in animal tissues in vivo, these complexes are presented in these tissues mainly in their diamagnetic, EPR-silent binuclear form.

在腹膜内注射N-乙酰基-L-半胱氨酸或谷胱甘肽，S-亚硝基谷胱甘肽，亚硝酸钠或血管扩张后的双核二亚硝基铁络合物腹膜内注射后，在小鼠体内和体外在小鼠肝脏中形成的亚硝酰基铁与二乙基二硫代氨基甲酸酯的复合物水平药物异山梨醇二硝酸盐（Isoket®）已通过电子顺磁共振（EPR）进行了评估。接受双核二亚硝基铁配合物与含硫醇配体或S的小鼠的配合物水平与亚硝酸盐或亚硝酸异山梨酯的硝酸盐处理后相比，用强还原剂连二亚硫酸盐处理肝脏制剂后，亚硝基谷胱甘肽没有变化。可以推断，在后一种情况下，在亚硝酸盐与Fe 2 ^+-二乙基二硫代氨基甲酸酯和Fe ³⁺形成的NO反应中，在不存在连二亚硫酸盐的情况下，生成了具有二乙基二硫代氨基甲酸酯的EPR活性单亚硝酰基铁络合物。-二乙基二硫代氨基甲酸酯配合物。在前一种情况下，具有亚乙基二硫代氨基甲酸酯的单亚硝基铁配合物是通过将双核二亚硝基配合物的已经存在的铁-二亚硝酰基基团中的铁-单亚硝酰基片段过渡而产生的，其含量比这些配合物的单核形式的含量高三至四倍。在组织中。我们获得的结果表明，当引入体内或由内源性NO参与产生的具有亚硫醇配体的二亚硝基铁配合物出现在体内动物组织中时，这些配合物主要以抗磁性EPR的形式存在于这些组织中。 -沉默的双核形式。